NO20092035L - Tiazolylforbindelser anvendbare som kinaseinhibitorer - Google Patents
Tiazolylforbindelser anvendbare som kinaseinhibitorerInfo
- Publication number
- NO20092035L NO20092035L NO20092035A NO20092035A NO20092035L NO 20092035 L NO20092035 L NO 20092035L NO 20092035 A NO20092035 A NO 20092035A NO 20092035 A NO20092035 A NO 20092035A NO 20092035 L NO20092035 L NO 20092035L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- compounds useful
- thiazolyl compounds
- thiazolyl
- formula
- Prior art date
Links
- 125000000335 thiazolyl group Chemical group 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87087206P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/088124 WO2008079873A2 (en) | 2006-12-20 | 2007-12-19 | Thiazolyl compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092035L true NO20092035L (no) | 2009-07-15 |
Family
ID=39563189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092035A NO20092035L (no) | 2006-12-20 | 2009-05-26 | Tiazolylforbindelser anvendbare som kinaseinhibitorer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8148400B2 (enExample) |
| EP (1) | EP2099794B1 (enExample) |
| JP (1) | JP5225288B2 (enExample) |
| CN (1) | CN101652363B (enExample) |
| NO (1) | NO20092035L (enExample) |
| WO (1) | WO2008079873A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679406B (zh) * | 2007-04-10 | 2013-07-10 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑基化合物 |
| EP2559771A3 (en) | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
| WO2015154022A1 (en) * | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN106932502B (zh) * | 2015-12-31 | 2021-05-18 | 上海奥博生物医药股份有限公司 | 一种索拉菲尼中4-氯-2-吡啶甲酸甲酯含量的测定方法 |
| CN107043375B (zh) * | 2017-04-28 | 2020-03-20 | 江苏食品药品职业技术学院 | 一种制备达沙替尼及其中间体的新方法 |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| KR102253652B1 (ko) * | 2019-08-19 | 2021-05-18 | 주식회사 셀젠텍 | 신규한 암전이 억제 활성을 갖는 화합물, 이의 제조방법 및 상기 화합물을 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 약학적 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1347971B1 (en) * | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| ATE479667T1 (de) * | 2003-02-06 | 2010-09-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
| CN101679406B (zh) * | 2007-04-10 | 2013-07-10 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑基化合物 |
-
2007
- 2007-12-19 US US12/519,597 patent/US8148400B2/en active Active
- 2007-12-19 WO PCT/US2007/088124 patent/WO2008079873A2/en not_active Ceased
- 2007-12-19 CN CN2007800515523A patent/CN101652363B/zh not_active Expired - Fee Related
- 2007-12-19 JP JP2009543183A patent/JP5225288B2/ja not_active Expired - Fee Related
- 2007-12-19 EP EP07869520.2A patent/EP2099794B1/en active Active
-
2009
- 2009-05-26 NO NO20092035A patent/NO20092035L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2099794A2 (en) | 2009-09-16 |
| CN101652363A (zh) | 2010-02-17 |
| WO2008079873A2 (en) | 2008-07-03 |
| EP2099794B1 (en) | 2013-05-15 |
| US8148400B2 (en) | 2012-04-03 |
| JP2010514686A (ja) | 2010-05-06 |
| JP5225288B2 (ja) | 2013-07-03 |
| WO2008079873A3 (en) | 2008-10-02 |
| US20100048581A1 (en) | 2010-02-25 |
| CN101652363B (zh) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090025L (no) | Pyrrolotriazinkinaseinhibitorer | |
| NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer | |
| NO20091708L (no) | Nye kinase inhibitorer | |
| MX2007015863A (es) | Inhibidores de esfingosina cinasa. | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20062136L (no) | Imidazopyrazintyrosin-kinaseinhibitorer | |
| NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| NO20075113L (no) | Proteinkinaseinhibitorer | |
| NO20091265L (no) | Pyrrolopyrazin som Syk-kinase inhibitor | |
| EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| NO20070199L (no) | Substituerte kinazoloner som anti-kreftmidler | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
| NO20083207L (no) | Inhibitorer av IAP | |
| NO20082496L (no) | Pyrazinderivater | |
| EA200900136A1 (ru) | Пирролопиримидины для фармацевтических композиций | |
| NO20070526L (no) | Kinazolindionderivater som parp-inhibitorer | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| NO20070655L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |